Literature DB >> 33141804

Race, Education, and Gender Disparities in Transplantation of Kidneys From Hepatitis C Viremic Donors.

Tiffany Nguyen1, Meghan E Sise2, Cindy Delgado3, Winfred Williams2, Peter Reese4,5, David Goldberg3.   

Abstract

BACKGROUND: Transplantation of kidneys from hepatitis C virus (HCV)-viremic donors into HCV-negative patients followed by direct-acting antiviral therapy was an important breakthrough to increase the number of life-saving kidney transplants. Data suggest that these transplants offer several benefits; however, it is unknown whether adoption of this practice has been shared equitably, especially among disadvantaged groups.
METHODS: We evaluated United Network for Organ Sharing data on HCV-seronegative adult deceased-donor kidney transplant recipients from January 1, 2017, to June 12, 2020. We compared recipients of a kidney from an HCV antibody- (Ab-)/nucleic acid test- (NAT-), HCV Ab+/NAT-, and HCV NAT+ donor. The primary covariates were as follows: (1) race/ethnicity; (2) female sex; and (3) highest level of education. Models included variables associated with being offered an HCV NAT+ kidney. We fit mixed-effects multinomial logistic regression models with the center as a random effect to account for patient clustering.
RESULTS: Of 48 255 adult kidney-alone deceased-donor kidney transplant HCV-seronegative recipients, 1641 (3.4%) donors were HCV NAT+-, increasing from 0.3% (January 2017-June 2017) to 6.9% (January 2020-June 2020). In multivariable models, racial/ethnic minorities, women, and those with less education were significantly less likely to receive a kidney from an HCV NAT+ donor relative to an HCV Ab-/NAT- and HCV Ab+/NAT- donor. The disparities were most pronounced among Hispanic and Asian patients with less educational attainment (grade school, high school, or some college/tech school).
CONCLUSIONS: Despite an increase in transplants from HCV NAT+ donors, we found substantial racial/ethnic disparities in transplantation of these kidneys. These data highlight how the benefits of a scientific breakthrough are often made less available to disadvantaged patients.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33141804      PMCID: PMC8842824          DOI: 10.1097/TP.0000000000003511

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  46 in total

1.  Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients.

Authors:  David S Goldberg; Peter L Abt; Emily A Blumberg; Vivianna M Van Deerlin; Matthew Levine; K Rajender Reddy; Roy D Bloom; Susanna M Nazarian; Deirdre Sawinski; Paige Porrett; Ali Naji; Richard Hasz; Lawrence Suplee; Jennifer Trofe-Clark; Anna Sicilia; Maureen McCauley; Midhat Farooqi; Caren Gentile; Jennifer Smith; Peter P Reese
Journal:  N Engl J Med       Date:  2017-04-30       Impact factor: 91.245

2.  Neighborhood Poverty and Sex Differences in Live Donor Kidney Transplant Outcomes in the United States.

Authors:  Tanjala S Purnell; Xun Luo; Deidra C Crews; Sunjae Bae; Jessica M Ruck; Lisa A Cooper; Morgan E Grams; Macey L Henderson; Madeleine M Waldram; Morgan Johnson; Dorry L Segev
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

3.  Use of Hepatitis C Virus Antibody-Positive Donor Livers in Hepatitis C Nonviremic Liver Transplant Recipients.

Authors:  Keith Luckett; Tiffany E Kaiser; Khurram Bari; Kamran Safdar; Michael R Schoech; Senu Apewokin; Tayyab S Diwan; Madison C Cuffy; Nadeem Anwar; Shimul A Shah
Journal:  J Am Coll Surg       Date:  2018-12-23       Impact factor: 6.113

4.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

Authors:  R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port
Journal:  N Engl J Med       Date:  1999-12-02       Impact factor: 91.245

Review 5.  Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation.

Authors:  James R Burton; Norah A Terrault; David S Goldberg; Roy D Bloom; Richard Gilroy; Julie K Heimbach; Robert S Brown; Gregory T Everson; Erin Rubin; Russ Wiesner; Elizabeth A Pomfret
Journal:  Transplantation       Date:  2020-03       Impact factor: 4.939

6.  Liver transplant center variability in accepting organ offers and its impact on patient survival.

Authors:  David S Goldberg; Benjamin French; James D Lewis; Frank I Scott; Ronac Mamtani; Richard Gilroy; Scott D Halpern; Peter L Abt
Journal:  J Hepatol       Date:  2015-11-25       Impact factor: 25.083

7.  National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.

Authors:  Vishnu S Potluri; David S Goldberg; Sumit Mohan; Roy D Bloom; Deirdre Sawinski; Peter L Abt; Emily A Blumberg; Chirag R Parikh; James Sharpe; K Rajender Reddy; Miklos Z Molnar; Meghan Sise; Peter P Reese
Journal:  J Am Soc Nephrol       Date:  2019-09-12       Impact factor: 10.121

8.  Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.

Authors:  Deirdre Sawinski; Kimberly A Forde; Vincent Lo Re; David S Goldberg; Jordana B Cohen; Jayme E Locke; Roy D Bloom; Colleen Brensinger; Joe Weldon; Justine Shults; Peter P Reese
Journal:  Am J Kidney Dis       Date:  2019-01-29       Impact factor: 8.860

9.  Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia.

Authors:  Michael E de Vera; Michael L Volk; Ziphezinhle Ncube; Shawna Blais; Melissa Robinson; Nancy Allen; Ryan Evans; Jill Weissman; Pedro Baron; Arputharaj Kore; Charles Bratton; Gwendolyn Garnett; Thanh Hoang; Philip Wai; Rafael Villicana
Journal:  Am J Transplant       Date:  2018-08-27       Impact factor: 8.086

10.  Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.

Authors:  Meghan E Sise; David S Goldberg; Jens J Kort; Douglas E Schaubel; Rita R Alloway; Christine M Durand; Robert J Fontana; Robert S Brown; John J Friedewald; Stacey Prenner; J Richard Landis; Melissa Fernando; Caitlin C Phillips; E Steve Woodle; Adele Rike-Shields; Kenneth E Sherman; Nahel Elias; Winfred W Williams; Jenna L Gustafson; Niraj M Desai; Brittany Barnaba; Silas P Norman; Mona Doshi; Samuel T Sultan; Meredith J Aull; Josh Levitsky; Dianne S Belshe; Raymond T Chung; Peter P Reese
Journal:  J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 10.121

View more
  2 in total

1.  Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections.

Authors:  Zoe A Stewart; Jeffrey Stern; Nicole M Ali; Harmit S Kalia; Karen Khalil; Srijana Jonchhe; Elaina P Weldon; Rebecca A Dieter; Tyler C Lewis; Nur Funches; Sudara Crosby; Monique Seow; Jonathan C Berger; Nabil N Dagher; Bruce E Gelb; Anthony C Watkins; Nader Moazami; Deane E Smith; Zachary N Kon; Stephanie H Chang; Alex Reyentovich; Luis F Angel; Robert A Montgomery; Bonnie E Lonze
Journal:  Transplant Direct       Date:  2021-09-07

2.  Graft survival differences in kidney transplants related to recipient sex and age.

Authors:  Asuncion Sancho; Eva Gavela; Julia Kanter; Sandra Beltrán; Cristina Castro; Verónica Escudero; Jonay Pantoja; Pablo Molina; Belen Vizcaíno; Mercedes González; Emma Calatayud; Ana Avila
Journal:  Front Med (Lausanne)       Date:  2022-09-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.